HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Friday, 26 July 2013

NICE minded no to rituximab for ANCA associated vasculitis

NICE is minded not to recommend rituximab (MabThera, Roche Products) in combination with glucocorticoids as an option for inducing remission in adults with a type of vasculitis (inflammation of the blood vessels) called anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis.

An issue of interest in the ERG report produced by Nick Latimer, Ruth Wong, Paul Tappenden and Chris Carroll in HEDS, is the spectacularly different model structure and data sources used by the ERG and manufacturer.  It is no wonder that the Committee has asked for a revised economic model from the manufacturer with a series of amendments.